Gene:
SULT1A1
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all SULT1A1 variant annotations

Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA *1 N/A N/A N/A
No VIP available No VIP available VA *2 N/A N/A N/A
rs1801030 22382G>A, 28557485C>T, 28617485C>T, 433G>A, 667G>A, SULT1A1*3, SULT1A1:667A>G, SULT1A1:Met223Val, Val145Met, Val223Met
C > T
Not Available
Val223Met
rs3760091 -36+452G>A, -36+452G>C, -425G>A, -425G>C, -5+452G>A, -5+452G>C, -624G>A, -624G>C, 139-2402G>A, 139-2402G>C, 19067G>A, 19067G>C, 28560800C>G, 28560800C>T, 28620800C>G, 28620800C>T, SULT1A1: -624G>C
C > G
C > T
5' Flanking
rs750155 -197G>A, -35-361G>A, -396G>A, -4-392G>A, 139-2174G>A, 19295G>A, 28560572C>T, 28620572C>T, SULT1A1: -396 G>A
C > T
5' UTR
rs9282861 22353G>A, 28557514C>T, 28617514C>T, 404G>A, 638G>A, Arg135His, Arg213His, SULT1A1*2, SULT1A1:638G>A:SULT1A1:Arg213His
C > T
Not Available
Arg213His
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142

Overview

Alternate Names:  STP; STP1
Alternate Symbols:  P-PST
PharmGKB Accession Id: PA343

Details

Cytogenetic Location: chr16 : p12.1 - p11.2
GP mRNA Boundary: chr16 : 28616913 - 28634866
GP Gene Boundary: chr16 : 28613913 - 28644866
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Cytosolic sulfotransferase 1A1 subfamily members catalyze the sulfate conjugation of phenolic compounds including steroid hormones, catecholamines and phenolic drugs, and also participate in the bioactivation of procarcinogens, reviewed in [Article:9141497]. The endogenous cosubstrate 3'-phosphoadenosine 5'-phosphate (PAPS) acts as the sulfate donor. Sulfotransferase 1A1 (SULT1A1) metabolizes several phenolic substrates including simple phenolic compounds (4-nitrophenol, which is used as a probe substrate [Article:10441143, 8423770]); drugs (acetaminophen [Article:6957279], minoxidil [Article:2390100]); estrogens (estrone, B-estradiol [Article:9068609], 2-hydroxyestrone, 2-hydroxyestradiol, 4-hydroxyestrone, 4-hydroxyestradiol [Article:11906176]), and synthetic estrogenic compounds (trans-4-hydroxytamoxifen [Article:12034366], diethylstilbestrol [Article:9068609], 2-methoxy estradiol [Article:11062153]). 2,6-dichloro-4-nitrophenol inhibits SULT1A1 activity [Article:6573904, 6576122, 1687013]. SULT1A1 also bioactivates procarcinogens including N-hydroxy metabolites of 2-amino-3-methylimidazo[4,5-f\]\quinoline [Article:16708048], and other procarcinogens [Article:9141497].



The SULT1A1 gene was cloned in 1996 [Article:9014197] and resides on chromosome 16 in close proximity to the three other members of the SULT1A subfamily: SULT1A2, SULT1A3 and SULT1A4 [Article:8912648, 15358107]. The gene consists of 7 coding exons and 2 alternatively spliced upstream non-coding exons. The 885-nucleotide open reading frame encodes a 295 amino acid protein. SULT1A1 protein is present in many human tissues, including liver, kidney and platelets [Article:9345314].



Large individual variations in SULT1A1 enzyme activity have been observed, with platelet enzyme activity varying more than 50-fold and thermal stability varying over 10-fold in 905 subjects [Article:9345314]. Three non-synonymous SNPs were identified in SULT1A1 and one allele, rs9282861(213Arg>His, 638G>A), with an allele frequency of \~30% was shown to be associated with both low activity and thermal stability in the platelet and low thermal stability in the liver [Article:9345314, 10413297]. Three additional amino acid sequence variants (Met223Val, Arg37Gln, Phe247Leu) have also been reported with allele frequencies less than 2% in a Caucasian population [Article:10413297, 16801938]. Other SNPs within the 5'-flanking region have been reported to influence enzymatic activity, and are in linkage disequilibrium with rs9282861 [Article:15970794]. Finally, copy number variants of functional significance have also recently been reported [Article:17189289].



On account of the importance of sulfation in the metabolism and biotransformation of estrogen and other steroid hormones, rs9282861 has been extensively studied in relationship with hormone-dependent cancers. To date, the studies have been inconclusive with varying results. This gene has also been implicated in other malignancies including colorectal and esophageal cancer [Article:16425401, 16272171].

Citation Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenetics and genomics. 2009. Hildebrandt Michelle, Adjei Araba, Weinshilboum Richard, Johnson Julie A, Berlin Dorit S, Klein Teri E, Altman Russ B. PubMed
History

Submitted by Michelle Hildebrandt, Araba Adjei, Richard Weinshilboum, and Julie A. Johnson (PPII), Dorit Berlin

Variant Summaries rs1801030, rs3760091, rs750155, rs9282861
Haplotype Summaries *2, -624G>C and -396A>G
Drugs
Chemical (1)
procarcinogens
Chemical Substrate (1)
4-nitrophenol
Chemical Inhibitor (1)
2,6-dichloro-4-nitrophenol
Diseases

Haplotype Overview

Haplotypes were extracted from [Article:16801938].

Source: PharmGKB

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Acetaminophen Pathway, Pharmacokinetics
    Stylized diagram showing acetaminophen metabolism and transport in the liver and kidney.
  1. Aromatase Inhibitor Pathway (Multiple Tissues), Pharmacodynamics
    Diagrammatic representation of the synthesis of estrogen in post-menopausal women and its blockade by aromatase inhibitors.
  1. Estrogen Metabolism Pathway
    Estrogen metabolism in the liver.
  1. Tamoxifen Pathway, Pharmacokinetics
    Tamoxifen metabolism in the liver.

External Pathways

Links to non-PharmGKB pathways.

  1. Cytosolic sulfonation of small molecules - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
estrogens

Curated Information ?

Publications related to SULT1A1: 41

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenetics and genomics. 2013. Innocenti Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics. 2011. Moyer Ann M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. The pharmacogenomics journal. 2010. Serrano D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology. Clinical pharmacology and therapeutics. 2009. Leeder J S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause (New York, N.Y.). 2010. Rebbeck Timothy R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenetics and genomics. 2009. Hildebrandt Michelle, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphic drug metabolism in anaesthesia. Current drug metabolism. 2009. Restrepo Juan G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008. Cotterchio Michelle, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Case-control study and meta-analysis of SULT1A1 Arg213His polymorphism for gene, ethnicity and environment interaction for cancer risk. British journal of cancer. 2008. Kotnis A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacology & therapeutics. 2008. Hines Ronald N. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth defects research. Part A, Clinical and molecular teratology. 2008. Adjei Araba A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population. International urology and nephrology. 2008. Koike Hidekazu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic diversity and function in the human cytosolic sulfotransferases. The pharmacogenomics journal. 2007. Hildebrandt M A T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human SULT1A1 gene: copy number differences and functional implications. Human molecular genetics. 2007. Hebbring Scott J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast cancer research : BCR. 2007. Wegman Pia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clinical pharmacology and therapeutics. 2006. Oscarson Mikael, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. Journal of the National Cancer Institute. 2006. Rebbeck Timothy R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. The pharmacogenomics journal. 2006. Mikhailova O N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women. Pharmacogenetics and genomics. 2005. Sillanpää Pia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alternate pathways of thyroid hormone metabolism. Thyroid : official journal of the American Thyroid Association. 2005. Wu Sing-Yung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common genetic polymorphisms in the 5'-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity. Pharmacogenetics and genomics. 2005. Ning Baitang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute. 2005. Jin Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. International journal of cancer. Journal international du cancer. 2005. Cheng Ting-Chih, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast cancer research : BCR. 2005. Wegman Pia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants of the sulfotransferase 1A1 and breast cancer risk. Breast cancer research and treatment. 2004. Langsenlehner Uwe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Sulfotransferase 1A1 (SULT1A1) polymorphism and breast cancer risk in Chinese women. Toxicology letters. 2004. Han Ding-Fen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics. 2004. Blanchard Rebecca L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2004. Nowell Susan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antihypertensive drug responses. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2004. Schwartz Gary L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in the treatment of breast cancer. The pharmacogenomics journal. 2004. Stearns V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk. International journal of cancer. Journal international du cancer. 2003. Saintot Monique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. British journal of clinical pharmacology. 2003. Hamdy Samar I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. Journal of the National Cancer Institute. 2002. Nowell Susan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Catecholestrogen sulfation: possible role in carcinogenesis. Biochemical and biophysical research communications. 2002. Adjei Araba A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Phenol sulphotransferase SULT1A1 polymorphism in prostate cancer: lack of association. Archives of toxicology. 2000. Steiner M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochemical pharmacology. 1999. Raftogianis R B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochemical and biophysical research communications. 1997. Raftogianis R B, et al. PubMed

LinkOuts

UniProtKB:
ST1A1_HUMAN (P50225)
Ensembl:
ENSG00000196502
GenAtlas:
SULT1A1
GeneCard:
SULT1A1
MutDB:
SULT1A1
ALFRED:
LO171038U
HuGE:
SULT1A1
Comparative Toxicogenomics Database:
6817
ModBase:
P50225
HumanCyc Gene:
HS09898
HGNC:
11453

Common Searches